New developments in massive transfusion in trauma

Current Opinion in Anaesthesiology

Volumn 23, Issue 2, 2010, Pages 246-250

  Greer, Sarah E ^a   Rhynhart, Kurt K ^a   Gupta, Rajan ^a   Corwin, Howard L ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Department of Anesthesiology ^*  (United States)

Author keywords

Factor VIIa; Massive transfusion; Thrombelastography; Transfusion ratios

Indexed keywords

BLOOD CLOTTING FACTOR 7A; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ACIDOSIS; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION; BLUNT TRAUMA; CLINICAL TRIAL; EARLY INTERVENTION; ERYTHROCYTE TRANSFUSION; FLUID RESUSCITATION; HUMAN; HYPOTHERMIA; HYPOVOLEMIA; INJURY; MORTALITY; PENETRATING TRAUMA; PLASMA TRANSFUSION; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY; TRANSFUSION;

BLOOD COAGULATION DISORDERS; BLOOD TRANSFUSION; FACTOR VIIA; HUMANS; RECOMBINANT PROTEINS; RESUSCITATION; THROMBELASTOGRAPHY; WOUNDS AND INJURIES;

EID: 77952158901     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e328336ea59     Document Type: Review

References (85)

1. Committee on Injury Prevention and Control, Institute of Medicine. Reducing the burden of injury: advancing prevention and treatment. Washington, District of Columbia: National Academy Press; 1999.
2. Krug EG, Sharma GK, Lozano R. The global burden of injuries. Am J Public Health 2000;90:523-526.
3. Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: a reassessment. J Trauma 1995;38:185-193.
4. Grounds RM, Seebach C, Knothe C, et al. Use of recombinant activated factor VII (Novoseven) in trauma and surgery: analysis of outcomes reported to an international registry. J Intensive Care Med 2006;21:27-39.
5. Wudel JH, Morris JA Jr, Yates K, et al. Massive transfusion: outcome in blunt trauma patients. J Trauma 1991;31:1-7.
6. Ferrara A, MacArthur JD, Wright HK, et al. Hypothermia and acidosis worsen coagulopathy in the patient requiring massive transfusion. Am J Surg 1990;160:515-518.
7. Engstrom M, Schott U, Romner B, et al. Acidosis impairs the coagulation: a thromboelastographic study. J Trauma 2006;61:624-628.
8. Eastridge BJ, Owsley J, Sebesta J, et al. Admission physiology criteria after injury on the battlefield predict medical resource utilization and patient mortality. J Trauma 2006;61:820-823.
9. Davis JW, Parks SN, Kaups KL, et al. Admission base deficit predicts transfusion requirements and risk of complications [see comment]. J Trauma 1996;41:769-774.
10. Gentilello LM, Jurkovich GJ, Stark MS, et al. Is hypothermia in the victim of major trauma protective or harmful? A randomized, prospective study. Ann Surg 1997;226:439-447;
11. discussion 447-449.
12. Martin RS, Kilgo PD, Miller PR, et al. Injury-associated hypothermia: an analysis of the 2004 National Trauma Data Bank. Shock 2005;24:114-118.
13. Holcomb JB, Jenkins D, Rhee P, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma 2007;62:307-310.
14. Spinella PC, Perkins JG, Grathwohl KW, et al. Warm fresh whole blood is • independently associated with improved survival for patients with combatrelated traumatic injuries. J Trauma 2009;66: S69-S76. A retrospective review demonstrating improved 24 h and 30-day survival in patients who received FWB during massive transfusion in a military setting.
15. Rotondo MF, Zonies DH. The damage control sequence and underlying logic. Surg Clin North Am 1997;77:761-777.
16. Schwab CW. Introduction: damage control at the start of 21st century. Injury 2004;35:639-641.
17. Holcomb JB, Helling TS, Hirshberg A. Military, civilian, and rural application of the damage control philosophy. Mil Med 2001;166:490-493.
18. Beekley AC, Beekley AC. Damage control resuscitation: a sensible approach • to the exsanguinating surgical patient. Crit Care Med 2008;36: S267-S274. A comprehensive review of damage control resuscitation.
19. Hess JR, Holcomb JB, Hoyt DB, et al. Damage control resuscitation: the need for specific blood products to treat the coagulopathy of trauma. Transfusion 2006;46:685-686.
20. Cosgriff N, Moore EE, Sauaia A, et al. Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited. J Trauma 1997;42:857-861;
21. discussion 861-862.
22. Hirshberg A, Dugas M, Banez EI, et al. Minimizing dilutional coagulopathy in exsanguinating hemorrhage: a computer simulation. J Trauma 2003;54:454-463.
23. Brummel-Ziedins K, Whelihan MF, Ziedins EG, et al. The resuscitative fluid you choose may potentiate bleeding. J Trauma 2006;61:1350-1358.
24. Hess JR, Brohi K, Dutton RP, et al. The coagulopathy of trauma: a review of • mechanisms. J Trauma 2008;65:748-754. A comprehensive review of the pathophysiology of the coagulopathy of trauma
25. Ganter MT, Cohen MJ, Brohi K, et al. Angiopoietin-2, marker and mediator of endothelial activation with prognostic significance early after trauma? Ann Surg 2008;247:320-326.
26. Brohi K, Cohen MJ, Ganter MT, et al. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis [see comment]. J Trauma 2008;64:1211-1217;
27. discussion 1217.
28. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999;82:165-174.
29. Kermode JC, Zheng Q, Milner EP. Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor. Blood 1999;94:199-207.
30. Meng ZH, Wolberg AS, Monroe DM 3rd, et al. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003;55:886-891.
31. Brohi K, Cohen MJ, Ganter MT, et al. Acute traumatic coagulopathy: initiated by hypoperfusion - modulated through the protein C pathway? Ann Surg 2007;245:812-818.
32. Simmons RL, Collins JA, Heisterkamp CA, et al. Coagulation disorders in combat casualties. I. Acute changes after wounding. II. Effects of massive transfusion. III. Postresuscitative changes. Ann Surg 1969;169:455-482.
33. Niles SE, McLaughlin DF, Perkins JG, et al. Increased mortality associated with the early coagulopathy of trauma in combat casualties. J Trauma 2008;64:1459-1463;
34. discussion 1463-1465.
35. Malone DL, Hess JR, Fingerhut A, et al. Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. J Trauma 2006;60: S91 -S96.
36. Como JJ, Dutton RP, Scalea TM, et al. Blood transfusion rates in the care of acute trauma. Transfusion 2004;44:809-813.
37. Hoyt DB, Dutton RP, Hauser CJ, et al. Management of coagulopathy in the patients with multiple injuries: results from an international survey of clinical practice. J Trauma 2008;65:755-764;
38. discussion 764-755.
39. Cotton BA, Gunter OL, Isbell J, et al. Damage control hematology: the impact •• of a trauma exsanguination protocol on survival and blood product utilization. J Trauma 2008;64:1177-1182;
40. discussion 1182-1183. A well designed retrospective cohort demonstrating improved mortality rates and overall blood product usage after implementation of a MTP with increased plasma and platelet to RBC ratios.
41. Cotton BA, Au BK, Nunez TC, et al. Predefined massive transfusion protocols •• are associated with a reduction in organ failure and postinjury complications. J Trauma 2009;66:41-48;
42. discussion 48-49. A well designed retrospective cohort demonstrating decreased rates of multiorgan failure and severe sepsis after implementation of a MTP with increased plasma and platelet to RBC ratios.
43. Dente CJ, Shaz BH, Nicholas JM, et al. Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian level I trauma center. J Trauma 2009;66:1616-1624.
44. Ho AM, Karmakar MK, Dion PW, et al. Are we giving enough coagulation factors during major trauma resuscitation? Am J Surg 2005;190:479-484.
45. Hardaway RM, Hardaway RM. Wound shock: a history of its study and treatment by military surgeons [see comment]. Mil Med 2004;169:265-269.
46. Williamson LM, Lowe S, Love EM, et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports [see comment]. BMJ 1999;319:16-19.
47. Claridge JA, Sawyer RG, Schulman AM, et al. Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. Am Surg 2002;68:566-572.
48. Vaslef SN, Knudsen NW, Neligan PJ, et al. Massive transfusion exceeding 50 units of blood products in trauma patients. J Trauma 2002;53:291-295;
49. discussion 295-296.
50. Duchesne JC, Hunt JP, Wahl G, et al. Review of current blood transfusions strategies in a mature level I trauma center: were we wrong for the last 60 years? J Trauma 2008;65:272-276;
51. discussion 276-278.
52. Kashuk JL, Moore EE, Johnson JL, et al. Postinjury life threatening coagulopathy: is 1:1 fresh frozen plasma:packed red blood cells the answer? J Trauma 2008;65:261-270;
53. discussion 270-271.
54. Duchesne JC, Islam TM, Stuke L, et al. Hemostatic resuscitation during surgery improves survival in patients with traumatic-induced coagulopathy. J Trauma 2009;67:33-37;
55. discussion 37-39.
56. Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital [see comment]. J Trauma 2007;63:805-813.
57. Stinger HK, Spinella PC, Perkins JG, et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 2008;64: S79-S85;
58. discussion S85.
59. Snyder CW, Weinberg JA, McGwin G Jr, et al. The relationship of blood • product ratio to mortality: survival benefit or survival bias? J Trauma 2009;66:358-362;
60. discussion 362-364. Analysis of FFP:PRBC ratio as a time-varying covariate demonstrating survival bias as a contributor to the association between improved mortality and transfusion ratios.
61. Sperry JL, Ochoa JB, Gunn SR, et al. An FFP:PRBC transfusion ratio >/=1:1.5 is associated with a lower risk of mortality after massive transfusion. J Trauma 2008;65:986-993.
62. Gunter OL Jr, Au BK, Isbell JM, et al. Optimizing outcomes in damage control resuscitation: identifying blood product ratios associated with improved survival. J Trauma 2008;65:527-534.
63. Gonzalez EA, Moore FA, Holcomb JB, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma 2007;62:112-119.
64. Spinella PC, Perkins JG, Grathwohl KW, et al. Effect of plasma and red blood cell transfusions on survival in patients with combat related traumatic injuries. J Trauma 2008;64: S69-S77;
65. discussion S77-S78.
66. Teixeira PG, Inaba K, Shulman I, et al. Impact of plasma transfusion in massively transfused trauma patients. J Trauma 2009;66:693-697.
67. Repine TB, Perkins JG, Kauvar DS, et al. The use of fresh whole blood in massive transfusion. J Trauma 2006;60: S59-S69.
68. Kauvar DS, Holcomb JB, Norris GC, et al. Fresh whole blood transfusion: a controversial military practice. J Trauma 2006;61:181-184.
69. Butenas S, Brummel KE, Branda RF, et al. Mechanism of factor VIIa-dependent coagulation in hemophilia blood [see comment]. Blood 2002;99:923-930.
70. ten Cate H, Bauer KA, Levi M, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993;92:1207-1212.
71. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999;354:1879.
72. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials [see comment]. J Trauma 2005;59:8-15;
73. discussion 15-18.
74. Harrison TD, Laskosky J, Jazaeri O, et al. 'Low-dose' recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. J Trauma 2005;59:150-154.
75. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004;57:709-718;
76. discussion 718-719.
77. Martinowitz U, Kenet G, Lubetski A, et al. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 2002;49: S15-S20.
78. Geeraedts LM Jr, Kamphuisen PW, Kaasjager HA, et al. The role of recombinant factor VIIa in the treatment of life-threatening haemorrhage in blunt trauma. Injury 2005;36:495-500.
79. Rizoli SB, Nascimento B Jr, Osman F, et al. Recombinant activated coagulation factor VII and bleeding trauma patients. J Trauma 2006;61:1419-1425.
80. Perkins JG, Schreiber MA, Wade CE, et al. Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion. J Trauma 2007;62:1095-1099;
81. discussion 1099-1101.
82. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998;80:773-778.
83. Ganter MT, Hofer CK, Ganter MT, Hofer CK. Coagulation monitoring: current •• techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008;106:1366-1375. A comprehensive review of point-of-care technology, including measurement variables and proposed indications.
84. Jeger V, Zimmermann H, Exadaktylos AK, et al. Can RapidTEG accelerate the search for coagulopathies in the patient with multiple injuries? [See comment]. J Trauma 2009;66:1253-1257.
85. Plotkin AJ, Wade CE, Jenkins DH, et al. A reduction in clot formation rate and • strength assessed by thrombelastography is indicative of transfusion requirements in patients with penetrating injuries. J Trauma 2008;64: S64-S68. A retrospective cohort demonstrating the utility of TEG in guiding transfusion requirements.